ÂÜÀòÂÒÂ×

Ariel Feldstein is a Corporate Vice President of Liver & Kidney Disease Research at Novo Nordisk, overseeing research initiatives and strategic collaborations since July 2022. Concurrently, Ariel serves as a Professor of Pediatrics and Chief of the Division of Pediatric Gastroenterology at UC San Diego, a position held since 2011. Ariel co-founded Elgia Therapeutics, Inc. in 2019, focusing on innovative treatments for chronic inflammatory and fibrotic diseases, and was previously the Scientific Founder and a board member of Jecure Therapeutics, dedicated to developing therapies for non-alcoholic steatohepatitis and liver fibrosis from 2016 to 2018. Earlier experience includes serving as the Director of Research at the Cleveland Clinic's Pediatric Institute from 2004 to 2011. Ariel holds a Doctor of Medicine (MD) degree from the University of Buenos Aires.